CF
STOK icon

Corebridge Financial’s Stoke Therapeutics STOK Stock Holding History

Corebridge Financial’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,600
Closed -$117K – 2446
2025
Q1 		$117K Sell
17,600
-261
-1% -$2.43K ﹤0.01% 2364
2024
Q4 		$197K Sell
17,861
-1,155
-6% -$14.2K ﹤0.01% 2197
2024
Q3 		$234K Sell
19,016
-117
-0.6% -$1.66K ﹤0.01% 2139
2024
Q2 		$258K Buy
+19,133
New +$258K ﹤0.01% 2047

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Corebridge Financial's STOK Position: Q2 2025 in Review

Corebridge Financial sold out of Stoke Therapeutics (STOK) in Q2 2025, closing a stake of 17,600 shares — an estimated $117K sold.

Corebridge Financial first reported a position in STOK in Q2 2024 and held it in 4 quarters. The position peaked at $258K in Q2 2024. 133 funds tracked by Wall St. Rank hold STOK as of Q2 2025.

  • Corebridge Financial reported no remaining Stoke Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 17,600 Stoke Therapeutics shares in Q2 2025, an estimated $117K.
  • Corebridge Financial first reported a position in Stoke Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Stoke Therapeutics position peaked at $258K in Q2 2024.
  • 133 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.